With corporate headquarters in Cambridge, MA., TransMolecular (TMI) TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies that promise to improve outcomes for gliomas, metastatic brain tumors, and other aggressive cancers with limited treatment options. Their SBIR awards were all received in AL. Focused to extending survival and preserve quality of life for millions of cancer patients by providing therapies and delivery technologies that exclusively target malignant cells while avoiding interaction with normal, healthy cells, the firm offered TM601, a synthetic a polypeptide based on amino acid peptide derived from scorpion venom, which is used to treat cancer. Organized around therapies for glioma, metastatic brain tumors, and cancers, in March 2011. Eisai Inc. and its Morphotek Inc. division - protein and antibody therapeutics for cancer, inflammation, and infectious diseases - acquired full rights to a proprietary tumor-targeting peptide (TTP) technology from TransMolecular Inc.
